ARTV · Artiva Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $251.0K | - | $26.66M | $3.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $19.31M | - | $17.63M | $17.86M | $11.16M | - | $13.52M | $11.26M |
| SG&A | $5.12M | - | $5.26M | $4.95M | $3.59M | - | $4.81M | $3.86M |
| Total Operating Expenses | $24.43M | - | $22.90M | $22.81M | $14.74M | - | $15.85M | $16.19M |
| D&A | $666.0K | - | $600.0K | $600.0K | $587.0K | - | $600.0K | $600.0K |
| Operating Income | ($24.43M) | - | ($22.90M) | ($22.81M) | ($14.49M) | - | ($18.34M) | ($16.19M) |
| Interest Expense | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | ($23.52M) | - | ($21.53M) | ($21.25M) | ($20.31M) | - | ($17.47M) | ($11.28M) |
| EPS - Basic | ($0.95) | - | ($0.88) | ($0.87) | ($17.24) | - | $13.98 | ($22.00) |
| EPS - Diluted | ($0.95) | - | ($0.88) | ($0.87) | ($17.24) | - | $1.62 | ($22.00) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.95M | $26.70M | $25.51M | $28.47M | $30.40M | $40.23M | $65.89M | $53.50M |
| Accounts Receivable | - | - | - | - | - | $0 | $569.0K | $1.03M |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.29M | $355.0K | $848.0K | $1.22M | $2.04M | $1.12M | $1.22M | $614.0K |
| Current Assets | $88.74M | $112.67M | $129.52M | $149.07M | $170.00M | $188.63M | $150.56M | $49.75M |
| Total Assets | $105.95M | $130.94M | $148.86M | $169.39M | $191.26M | $209.58M | $225.60M | $105.11M |
| Current Liabilities | $10.88M | $13.09M | $11.12M | $10.77M | $12.20M | $12.25M | $13.29M | $10.83M |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $18.11M | $20.97M | $19.64M | $20.35M | $22.48M | $22.94M | $24.60M | $50.60M |
| Stockholders' Equity | $87.85M | $109.97M | $129.22M | $149.04M | $168.78M | $186.64M | $201.00M | ($164.25M) |
| Retained Earnings | ($354.06M) | ($330.55M) | ($309.78M) | ($288.25M) | ($267.00M) | ($246.68M) | ($230.59M) | ($181.31M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($20.95M) | - | - | - | ($15.09M) | - | - | - |
| Investing Cash Flow | $15.32M | - | - | - | $9.78M | - | - | - |
| Financing Cash Flow | ($112.0K) | - | - | - | $239.0K | - | - | - |
| CapEx | $242.0K | - | - | - | $18.0K | - | - | - |
| Free Cash Flow | ($21.19M) | - | - | - | ($15.10M) | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -5773.7% | - | -68.8% | -463.0% |
| EBITDA margin | - | - | - | - | -5539.8% | - | -66.5% | -445.8% |
| Net margin | - | - | - | - | -8092.0% | - | -65.5% | -322.7% |
| Free cash flow margin | - | - | - | - | -6017.5% | - | - | - |
| FCF / Net income | 0.90 | - | - | - | 0.74 | - | - | - |
| R&D / Revenue | - | - | - | - | 4444.6% | - | 50.7% | 322.0% |
| SG&A / Revenue | - | - | - | - | 1429.1% | - | 18.0% | 110.3% |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -22.2% | - | -14.5% | -12.5% | -10.6% | - | -7.7% | -10.7% |
| Return on equity | -26.8% | - | -16.7% | -14.3% | -12.0% | - | -8.7% | 6.9% |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 8.16 | 8.61 | 11.65 | 13.84 | 13.93 | 15.39 | 11.33 | 4.59 |
| Quick ratio | 8.16 | 8.61 | 11.65 | 13.84 | 13.93 | 15.39 | 11.33 | 4.59 |
| Cash ratio | 1.93 | 2.04 | 2.29 | 2.64 | 2.49 | 3.28 | 4.96 | 4.94 |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.21 | 1.19 | 1.15 | 1.14 | 1.13 | 1.12 | 1.12 | -0.64 |
| Liabilities / Assets | 0.17 | 0.16 | 0.13 | 0.12 | 0.12 | 0.11 | 0.11 | 0.48 |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | 0.00 | - | 0.12 | 0.03 |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | 8d | 108d |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | 9.5x | - |
| P / B | 1.8x | - | 0.5x | 0.2x | 0.0x | - | 1.5x | - |
| P / S | - | - | - | - | 9.7x | - | 11.0x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -68.6% | - | -24.9% | -40.9% | - | - | - | - |
| Net income growth (YoY) | -15.8% | - | -23.2% | -88.4% | - | - | - | - |
| EPS growth (YoY) | 94.5% | - | - | 96.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -40.3% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -48.0% | -41.1% | -35.7% | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Artiva Biotherapeutics against the 5 most active filers in the same SIC group.